Recent Achievements and Ongoing Developments at BioSig Technologies

The company BioSig Technologies, a pioneer in digital signal processing and intracardiac signal visualization with its proprietary PURE EPTM System, released an update to shareholders on January 19, 2023, highlighting recent milestones and company developments.

Live Patient Cases to be Supported by BioSig’s PURE EP System During EPLive 2020

BioSig Technologies (NASDAQ: BSGM) is a medical technology company which designs and commercializes an innovative signal processing platform. Bio Sig’s signal processing platform is aimed to uncover the full range of ECG and intra-cardiac signals and to improve signal fidelity.

BioSig Technologies has recently announced that during EPLive 2020, the fifth international symposium on complex arrhythmias, its first product, the PURE EP system, would be featured in several live cases broadcast.

Medical Device Manufacturing

In recent years, the medical device industry has grown steadily, driven by global technological advances, the digitization and incorporation of new technologies, the increasing demand by the population, placing the sector in a complete panorama of growth and development.

Today, different companies manufacture devices capable of measuring the heart rate, pressure, sugar levels and the general state of the patient's health in an easy and affordable way for the population. New information technologies allow real-time diagnostics and automate health measurements, reliably and at the patient's hand at home.

BioSig Technologies Commitment toward Quality Patient Care

Information technology has made significant contributions to our world, especially in the medical industry. Medical technology has evolved from introducing doctors to new equipment to use inside private practices and hospitals to connecting patients and doctors thousands of miles away through telecommunications. Even more, medical scientists and physicians are constantly conducting research and testing new procedures to help prevent, diagnose, and cure diseases as well as developing new drugs and medicines that can lessen symptoms or treat ailments.

For example, BioSig Technologies, a Connecticut-based medicaltechnology company working on advanced biomedical signal processing technology, has been able to improve fidelity of acquired cardiac signals that may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and related procedures. BioSig’s commitment toward offering higher quality of patient care by introducing innovative technological solutions to medicine, has yield some impressive growth in the medical device sector.

With more and more hospitals and practices using medical technology like mobile devices on the job, physicians can now have access to any type of information they need – from drug information, research and studies, patient history or records, and more – within mere seconds.  

Last November, BioSig had signed a research program deal with Mayo Clinic which consisted of several two-to-three-year projects, focusing on the development of additional advanced features of their first product, the PURE EP system, within the field of electrophysiology. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. 

BioSig’s ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia.

Led by their CEO Ken Londoner, a proven management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE  EPTM System. The technology has been developed to address an unmet need in a large and growing market. BioSig is currently focusing on the development of a proprietary biomedical signal processing platform, engineered to meet excess demand for technology in the electrophysiology (EP) marketplace.

PURE EP™ Simulator Gets a U.S. Patent

On June 06, 2019, BioSig Technologies, Inc., a Westport, Conn.-based company that develops a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its electrophysiology simulator. The patent application number 15/103,278 entitled, "Systems and Methods For Evaluation of Electrophysiology Systems" was filed on June 9, 2016.